Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions
- PMID: 25935522
- DOI: 10.1016/j.febslet.2015.04.032
Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions
Abstract
PTPRZ1-MET (ZM) proteins are a group of fusion proteins identified in human gliomas by high-throughput transcriptome sequencing. ZM fusions are associated with poor prognosis in afflicted glioma patients and mediate oncogenic effects in assays. In this study, we show that ZM-carrying patients have increased hepatocyte growth factor receptor (MET) mRNA expression levels induced by fusion with receptor-type tyrosine-protein phosphatase zeta (PTPRZ1). Furthermore, ZM fusions preserve fundamental properties of wild-type MET with respect to processing and dimerization, and enhance phosphorylation in an hepatocyte growth factor (HGF)-dependent and independent manner. Our findings suggest that ZM induces gliomas through elevated expression and phosphorylation of the MET oncoprotein.
Keywords: Dimerization; Expression level; Fusion gene; Hepatocyte growth factor receptor; Phosphorylation; Receptor-type tyrosine-protein phosphatase zeta.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.Genome Res. 2014 Nov;24(11):1765-73. doi: 10.1101/gr.165126.113. Epub 2014 Aug 18. Genome Res. 2014. PMID: 25135958 Free PMC article.
-
High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation.CNS Neurosci Ther. 2021 May;27(5):617-628. doi: 10.1111/cns.13627. Epub 2021 Feb 28. CNS Neurosci Ther. 2021. PMID: 33645009 Free PMC article.
-
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.Oncogene. 2017 Sep 21;36(38):5369-5381. doi: 10.1038/onc.2017.134. Epub 2017 May 15. Oncogene. 2017. PMID: 28504721 Free PMC article.
-
Protein Tyrosine Phosphatase Receptor Zeta 1 as a Potential Target in Cancer Therapy and Diagnosis.Int J Mol Sci. 2023 Apr 30;24(9):8093. doi: 10.3390/ijms24098093. Int J Mol Sci. 2023. PMID: 37175798 Free PMC article. Review.
-
Targeting gene fusions in glioma.Curr Opin Neurol. 2021 Dec 1;34(6):840-847. doi: 10.1097/WCO.0000000000000991. Curr Opin Neurol. 2021. PMID: 34766555 Review.
Cited by
-
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.Pharmaceuticals (Basel). 2024 Mar 30;17(4):448. doi: 10.3390/ph17040448. Pharmaceuticals (Basel). 2024. PMID: 38675409 Free PMC article.
-
An Observatory for the MET Oncogene: A Guide for Targeted Therapies.Cancers (Basel). 2023 Sep 21;15(18):4672. doi: 10.3390/cancers15184672. Cancers (Basel). 2023. PMID: 37760640 Free PMC article. Review.
-
The multiple paths towards MET receptor addiction in cancer.Oncogene. 2018 Jun;37(24):3200-3215. doi: 10.1038/s41388-018-0185-4. Epub 2018 Mar 19. Oncogene. 2018. PMID: 29551767 Review.
-
A novel PTPRZ1-ETV1 fusion in gliomas.Brain Pathol. 2020 Mar;30(2):226-234. doi: 10.1111/bpa.12776. Epub 2019 Aug 27. Brain Pathol. 2020. PMID: 31381204 Free PMC article.
-
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy.J Pediatr Pharmacol Ther. 2021;26(6):541-555. doi: 10.5863/1551-6776-26.6.541. Epub 2021 Aug 16. J Pediatr Pharmacol Ther. 2021. PMID: 34421403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous